Biotech's comeback kid: Endocyte, which Novartis just acquired for $2.1 bn

Biotech's comeback kid: Endocyte, which Novartis just acquired for $2.1 bn

STAT Plus: 2018’s comeback kid: Endocyte goes from nosedive to Novartis’ latest acquisition

By KATE SHERIDAN

ADOBE

Last year, Endocyte laid off nearly half the company. This year, shareholders voted to approve a $2.1 billion acquisition offer from Novartis.

READ MORE